What Celularity does

Celularity Inc. (NASDAQ: CELU) is a clinical-stage regenerative and cellular medicine company developing and commercializing off-the-shelf, cryopreserved, allogeneic cell therapies and advanced biomaterial products derived from the postpartum placenta, targeting age-related and degenerative diseases. Its core scientific platform, the Celularity IMPACT™ (Immuno-Modulatory Placental-derived Allogeneic Cell Therapy) system, operates from a 150,000 sq ft FDA-compliant cGMP facility in Florham Park, NJ, with nine Grade C/ISO-7 suites, six Grade D/ISO-8 labs, and 100+ specialized scientists. The pipeline includes placental-derived natural killer cell therapies (CYNK-001 and genetically-modified CYNK-101 with IND clearance for glioblastoma), allogeneic placental CAR-T cells with TCR knockout (CyCART), mesenchymal-like adherent stromal cells (PDA-001/PDA-002, marketed as cenplacel-L for physician-directed investigational use in Florida), and preclinical placental exosomes (pEXO); the wholly-owned Lifebank/LifebankUSA subsidiary provides private cellular banking subscription services for cord blood, cord tissue, and placental tissue.

Celularity's revenue model historically combined direct sales of biomaterial products (Biovance, Interfyl, CentaFlex, REBOUND, NATALIN, Biovance 3L Ocular) to wound care and orthopedic specialists, Lifebank subscription services, and CDMO offerings, with the biomaterials franchise out-licensed to NexGel in April 2026 for $13.3M upfront and up to $20.0M in milestones/royalties, leaving Celularity with exclusive manufacturing revenue from NexGel plus cenplacel-L commercialization via Fountain Life in Florida under Florida Statutes §458.3245 and §459.0127. Go-to-market motions are multi-pronged: enterprise field sales for physician access, channel partnerships for state-level investigational use, direct-to-consumer for Lifebank banking subscriptions, and OEM/licensing for the biomaterials franchise now handled by NexGel. Founded in 2017 as a spin-out from Celgene (tracing back to Anthrogenesis founded in 1998), Celularity became publicly traded on NASDAQ in 2021 and is led by Founder/Chairperson/CEO Robert J. Hariri, M.D., Ph.D., with recent additions including CCO Rick Gonzalez (May 2026) and Acting CFO John Sprague (February 2026).

Name

Celularity

Legal name

Celularity Inc.

Website

https://celularity.com

Company type

Public

Founded year

2017

Operating status

Operating

Headcount range

101–250 employees

Short description

Celularity Inc. is a clinical-stage regenerative medicine company developing off-the-shelf placental-derived allogeneic cell therapies (cenplacel-L, CYNK-001, CYNK-101, CyCART) and operating the Lifebank cellular banking subscription service, targeting age-related and degenerative diseases through its Florham Park, NJ cGMP manufacturing platform.

Ownership category

akta.pro rank

Product category

Regenerative Cell Therapy

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Blood and Organ Banks (621991)

SIC

Biological Products, (No Disgnostic Substances) (2836), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Pharmaceutical Preparations (2834)

akta.pro primary industry

Cell Therapy Manufacturing Services (GMP, autologous/allogeneic) (HLAAAKAC)

akta.pro secondary industries

Cell & Gene Therapy Chain-of-Identity/Chain-of-Custody Logistics (HLAGAMAE), Cell Banking & Viral Seed Services (MCB/WCB/VSB) (HLAGAGAD)

Keywords

• Regenerative medicine
• Allogeneic cell therapy
• Placental-derived biologics
• Cellular medicine manufacturing
• Cord tissue banking

Headquarters

HQ city

Florham Park

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. Advanced biomaterial product sales: Commercial sales of placental-derived biomaterial products including Biovance, Biovance 3L, Interfyl, CentaFlex, Natalin, REBOUND and Biovance 3L Ocular used in wound care, orthopedics, ocular surface reconstruction and surgical tendon management. Portfolio largely out-licensed to NexGel as of April 2026 with milestone payments and royalties, and Celularity retained exclusive manufacturing rights at its Florham Park facility.
2. Cenplacel-L cell therapy sales: Commercial sales of cenplacel-L (placental-derived allogeneic investigational cell therapy, also known as PDA-001/PDA-002) to licensed physicians in permissive regulatory markets starting in Florida under Florida Statutes § 458.3245 and § 459.0127, via Fountain Life channel; therapy has not received FDA approval for any indication.
3. Lifebank cellular banking subscription services: Private cellular banking subscription services for expectant parents and adults banking cord tissue, placental tissue and other cellular material via LifebankUSA platform; recurring consumer subscription revenue with over 20 years of operating history under predecessor brand.
4. Contract Development and Manufacturing Organization (CDMO) services: CDMO services for strategic partners using Celularity's integrated GMP manufacturing platform, supporting both internal programs and external customers in cell therapy and biomaterial production.
5. Licensing royalties and milestone payments (NexGel transaction): Up to $20.0 million in future milestone payments based on net sales thresholds and royalties on net sales of certain development-stage products licensed to NexGel as part of biomaterials portfolio transaction closed April 21, 2026.
6. Exclusive manufacturing revenue from NexGel: Ongoing manufacturing revenue stream from acting as exclusive manufacturer for NexGel-licensed biomaterial products at FDA-compliant Florham Park, NJ facility.

Pricing tiers

Go-to-market motion6 records

Core offering

Celularity develops and commercializes off-the-shelf, allogeneic, cryopreserved cell therapies and advanced biomaterial products derived from postpartum human placenta, including placental Natural Killer cell therapies (CYNK-001, CYNK-101), placental CAR-T cells (CyCART), placental mesenchymal-like adherent stromal cells (PDA-001/PDA-002 / cenplacel-L) and placental exosomes. The company also sells advanced biomaterial allografts (Biovance, Interfyl, CentaFlex, NATALIN, REBOUND, Acelagraft) and operates the LifebankUSA private cellular banking subscription service, with manufacturing performed at a 150,000 sq ft FDA-registered cGMP facility in Florham Park, NJ.

Product overview

Celularity operates a platform-plus-modules architecture anchored by its Celularity IMPACT™ fully integrated placental-derived cell therapy manufacturing platform (Immuno-Modulatory Placental-derived Allogeneic Cell Therapy) located at a 150,000 sq. ft. FDA-compliant cGMP facility in Florham Park, New Jersey. The company develops and commercializes off-the-shelf allogeneic cell therapy candidates and biomaterial products derived from the postpartum placenta. Core cellular therapy products include CYNK-001 (placental NK cells), CYNK-101 (genetically-modified NK cells with high-affinity CD16), CyCART (allogeneic P CAR-T cells with TCR knockout), PDA-001/PDA-002 MLASCs (marketed under the brand name cenplacel-L for physician-directed investigational use), and placental exosomes (pEXO) in pre-clinical development. The advanced biomaterials franchise encompasses Interfyl®, Biovance®, Biovance® 3L, CentaFlex®, Biovance 3L Ocular, REBOUND™, NATALIN™, and Acelagraft™, with pipeline programs including Celularity Tendon Wrap (CTW), FUSE Bone Void Filler, and Celularity Placental Matrix (CPM). The Lifebank / LifebankUSA cellular banking platform (operating since 1998) and Celularity's CDMO services round out the portfolio. In 2026, Celularity out-licensed its commercial biomaterials portfolio to NexGel for up to $35 million, narrowing strategic focus onto longevity-oriented placental-derived cell therapies.

Differentiator

Problem solved

Functional benefit

Brands

• Lifebank (LifebankUSA): Private cellular and tissue biobanking service offering cord blood, cord tissue, and placental tissue preservation for families, operating since 1998.
• CYNK-001
• CYNK-101
• CyCART
• PDA-001 / PDA-002
• Cenplacel-L
• Biovance
• Biovance 3L
• Interfyl
• CentaFlex
• NATALIN
• REBOUND
• Celularity IMPACT

Products and services

• Cenplacel-L (PDA-001/PDA-002 MLASCs) Proprietary formulation of Celularity's placental-derived allogeneic cell therapy (also referenced as PDA-001/PDA-002) positioned as the company's lead asset for physician-directed investigational use. Targets inflammation, degeneration and age-related disease, leveraging demonstrated immunomodulatory and regenerative properties of placental-derived mesenchymal-like adherent stromal cells.
• CYNK-001 Cryopreserved, allogeneic, off-the-shelf natural killer (NK) cell therapy derived from placental hematopoietic stem cells. Demonstrates perforin/granzyme B expression, cytolytic activity against hematological and solid tumor lines, IFN-γ secretion, and expression of NKG2D, CD94, DNAM1, NKp30, NKp44 and NKp46. In clinical development for acute myeloid leukemia, glioblastoma multiforme, multiple myeloma, and COVID-19.
• CYNK-101 Genetically-modified placental NK cells engineered to express a high-affinity cleavage-resistant CD16 Fc receptor to augment antibody-dependent cellular cytotoxicity (ADCC) in combination with monoclonal antibody therapeutics. FDA IND clearance obtained for glioblastoma multiforme.
• CyCART (Placental-derived CAR-T) Allogeneic cryopreserved chimeric antigen receptor T cell therapy derived from postpartum placental T cells, engineered with CAR expression and knockout of endogenous T cell receptors (P CAR-T). Targets hematologic and solid tumor indications.
• Placental Exosomes (pEXO) Off-the-shelf extracellular vesicles isolated from postpartum human placenta, expressing characteristic markers CD9, CD63 and CD81. Contain over a thousand proteins and microRNAs evaluated at pre-clinical stage for regenerative and age-related disease applications.
• Biovance / Biovance 3L / Biovance 3L Ocular Human amniotic membrane allograft (Biovance), tri-layer human amniotic membrane allograft (Biovance 3L) and tri-layer amniotic membrane formulation for ocular surface reconstruction (Biovance 3L Ocular) used in wound care and ophthalmic applications.
• Interfyl Human connective tissue matrix derived from placenta for soft tissue management; commercial-stage regenerative biomaterial product.
• CentaFlex Human placenta tissue matrix commercial product for advanced regenerative applications.
• NATALIN / Acelagraft Tri-layer amniotic membrane allograft (NATALIN) and wound care product (Acelagraft) derived from placenta, both receiving FDA Tissue Reference Group recommendation letters.
• REBOUND Placental-derived allograft acquired from Sequence LifeScience, Inc., expanding the commercial biomaterials portfolio.
• Lifebank (LifebankUSA) Cellular Banking Private client biobanking service offering cryopreservation of placenta and umbilical cord blood and tissue for expectant parents and adults, with on-site vapor-phase liquid-nitrogen storage monitored 24/7/365 and proprietary procurement systems.
• Celularity IMPACT Manufacturing & CDMO Services Contract Development and Manufacturing Organization (CDMO) services delivered through Celularity's integrated GMP manufacturing platform (Celularity IMPACT) at the 150,000 sq ft FDA-compliant Florham Park, NJ facility, supporting cell therapy and biomaterial production for external partners.

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

Feature8 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• MiMedx Group: MiMedx develops and commercializes placental-derived amniotic membrane and collagen-based regenerative products for wound care, orthopedics and surgical applications — directly comparable to Celularity's Biovance/Interfyl/CentaFlex/Natalin portfolio that was recently out-licensed to NexGel.
• Fate Therapeutics: Fate Therapeutics develops off-the-shelf allogeneic iPSC-derived NK and T-cell therapies (e.g., FT516, FT596) for oncology — directly comparable to Celularity's CYNK-001, CYNK-101 and CyCART allogeneic placental-derived cell therapy programs.
• Nkarta: Nkarta is a clinical-stage allogeneic NK cell therapy company targeting hematologic malignancies and autoimmune disease, providing a directly comparable allogeneic, off-the-shelf NK cell platform against Celularity's CYNK-001 and CYNK-101 programs.
• Pluristem Therapeutics: Pluristem develops placental-derived allogeneic mesenchymal-like stromal cell therapies (PLX cells) for regenerative medicine indications. Its cell source and manufacturing approach closely mirror Celularity's PDA-001/PDA-002 MLASC platform.
• Mesoblast: Mesoblast commercializes and develops allogeneic mesenchymal stromal cell therapies (Remestemcel-L, Rexlemestrocel-L) for inflammatory and degenerative diseases — directly comparable to Celularity's PDA-002 program in Crohn's disease, rheumatoid arthritis and diabetic foot ulcers.
• Century Therapeutics: Century Therapeutics develops allogeneic iPSC-derived NK and T-cell therapies (including CAR-T) for oncology — directly comparable to Celularity's CyCART allogeneic placental CAR-T with TCR knockout platform.
• Cryo-Cell International: Cryo-Cell is a direct competitor in private family cellular banking with a comparable cord blood and cord tissue cryopreservation subscription business, operating in the same U.S. consumer market as Celularity's Lifebank subsidiary.

Broad incumbents

• Organogenesis Holdings: Organogenesis is a leading commercial-stage regenerative medicine company selling skin substitutes and wound care biologics (Apligraf, Dermagraft, PuraPly). It competes head-to-head with Celularity's biomaterials franchise in the same physician channels and CMS reimbursement framework.
• Integra LifeSciences: Integra LifeSciences is a diversified regenerative medicine and surgical specialty company with skin substitutes, wound matrices and regenerative technologies (Integra Dermal Regeneration Template, AmnioExcel) overlapping Celularity's biomaterial wound care portfolio.

Emerging players

• Athersys: Athersys is a clinical-stage cell therapy company developing MultiStem, an allogeneic cell therapy for inflammatory, neurological and regenerative indications — comparable in modality and target indications to Celularity's MLASC and regenerative medicine pipeline.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/celularity
• Facebookfacebook.com/celularity
• LinkedInlinkedin.com/company/celularity

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles14 records

Subsidiaries1 record

Funding overview

Funding rounds6 records

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Celularity